PMID- 30248550
OWN - NLM
STAT- MEDLINE
DCOM- 20191121
LR  - 20191121
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 278
DP  - 2018 Nov
TI  - Incretin drugs as modulators of atherosclerosis.
PG  - 29-38
LID - S0021-9150(18)31373-X [pii]
LID - 10.1016/j.atherosclerosis.2018.09.011 [doi]
AB  - Atherosclerosis is a major underlying cause of ischemic heart diseases, ischemic 
      stroke, and peripheral artery disease. Atherosclerotic plaque progression is 
      characterized by chronic progressive inflammation of the arterial wall, 
      endothelial cell dysfunction, and subendothelial lipoprotein retention. Incretin 
      drugs, glucagon-like peptide-1 receptor (GLP-1R) agonists, and dipeptidyl 
      peptidase-IV (DPP-IV) inhibitors, are promising anti-hyperglycemic agents used 
      for the treatment of type 2 diabetes mellitus (T2DM). In addition to 
      glucose-lowering effects, emerging data suggest that incretin drugs have 
      anti-atherogenic effects with the potential to stabilize atherosclerotic plaques 
      and treat arterial inflammation. Clinical and preclinical studies have reported a 
      plethora of therapeutic benefits of incretin drugs, including modulation of 
      inflammatory response, reduction of intima-media thickening, improvement in lipid 
      profiles, endothelial and smooth muscle cell modulation. Despite extensive 
      research and widespread clinical use of incretin-based therapies, the research on 
      the incretin hormones continues to expand. This review outlines clinical studies, 
      molecular aspects, and potential therapeutic implications of incretin drugs in 
      attenuation of atherosclerosis.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Gallego-Colon, Enrique
AU  - Gallego-Colon E
AD  - Department of Biochemistry, Medical University of Silesia, School of Medicine in 
      Katowice, Poland. Electronic address: enrique.gce@gmail.com.
FAU - Wojakowski, Wojciech
AU  - Wojakowski W
AD  - Third Division of Cardiology, Medical University of Silesia, Katowice, Poland.
FAU - Francuz, Tomasz
AU  - Francuz T
AD  - Department of Biochemistry, Medical University of Silesia, School of Medicine in 
      Katowice, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180914
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Incretins)
RN  - 0 (Lipids)
RN  - 0 (Peptides)
SB  - IM
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Atherosclerosis/*drug therapy
MH  - Blood Glucose/analysis
MH  - Blood Pressure
MH  - Cardiovascular Diseases/prevention & control
MH  - Carotid Intima-Media Thickness
MH  - Diabetes Complications/drug therapy
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/pharmacology
MH  - Endothelium, Vascular/pathology
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Homeostasis
MH  - Humans
MH  - Incretins/*therapeutic use
MH  - Inflammation
MH  - Lipids/blood
MH  - Peptides/chemistry
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Cardiovascular diseases
OT  - DPP-IV
OT  - Endothelial cell function
OT  - Exenatide
OT  - GLP-1
OT  - Incretin
OT  - Incretin therapy
OT  - Sitagliptin
OT  - Vascular inflammation
EDAT- 2018/09/25 06:00
MHDA- 2019/11/22 06:00
CRDT- 2018/09/25 06:00
PHST- 2018/02/07 00:00 [received]
PHST- 2018/07/06 00:00 [revised]
PHST- 2018/09/13 00:00 [accepted]
PHST- 2018/09/25 06:00 [pubmed]
PHST- 2019/11/22 06:00 [medline]
PHST- 2018/09/25 06:00 [entrez]
AID - S0021-9150(18)31373-X [pii]
AID - 10.1016/j.atherosclerosis.2018.09.011 [doi]
PST - ppublish
SO  - Atherosclerosis. 2018 Nov;278:29-38. doi: 10.1016/j.atherosclerosis.2018.09.011. 
      Epub 2018 Sep 14.